Phase 3 N=364 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=433 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
Depression
Primary: Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30) — -17.9; -21.7; -20.8 units on a…
Phase 3 N=978 A Study in Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.51; -1.30; -0.99; -0.46 percentage of glycosylated hemoglobin — p=<0.001
Phase 3 N=119 Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Mean Change From Baseline in Schiff Sensitivity Score — 2.26; 2.25; 2.09; 0.78 Score on a scale — p=<0.0001
N/A N=20 Comparison of Two Devices Using Near-infra Red Spectroscopy During a Vascular Occlusion Test
Healthy
Primary: Change of Tissue Oxygenation Value During Ischemia and Reperfusion Period Until Basline Value Was Achieved — 17.9; 13.5; 280.0; 186.5 %/min — p=<0.05
Phase 3 N=92 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
Venous Thromboembolism
Primary: The Incidence of Major or Clinically Relevant Non-major Bleeding — 3.4; 6.9 percentage of subjects with bleeds
Phase 3 N=80 Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
Venous Thromboembolism
Primary: Incidence of Any Adjudicated Bleeding Events — 33.3; 14.3; 22.7; 40.0 percentage of subjects with bleeds
Phase 2 N=54 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
Breast Neoplasms
Primary: Confirmed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 25.0; 42.3 Percentage of participants
Phase 2 N=23 Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Primary: Percentage of Patients With TMA Event-free Status — 80 Percentage of Participants
Phase 3 N=439 Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 93.4; 88.1 percentage of participants — p=0.066
Phase 4 N=28 Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Congestion
Nasal Congestion
Primary: Anatomical Measures : Cross Sectional Area — 133.22; 116.88; 156.48; 176.12 mm^2 — p=<0.0001
N/A N=128 Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder
Cognition Disorders
Primary: Multiple Sclerosis Neuropsychological Screening Questionnaire-Patient Version — 33.58; 36.35 units on a scale
N/A N=30 Promoting Physical Activity Behavior in Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Changes From Baseline in Physical Activity Behavior — 14.36; 16.22; 33.07; 21.00 scores on a scale
Phase 2 N=40 Pharmacokinetic Study of 4 mg Nicotine Lozenge.
Smoking Cessation
Primary: Area Under the Curve From Time 0 to t, AUC (0-t) — 89.14; 87.38; 86.60; 91.97 nanograms (ng)*hours (h)/milliliter (mL)
Phase 4 N=46 Milnacipran for Chronic Pain in Knee Osteoarthritis
Knee Osteoarthritis · Degenerative Joint Disease · Chronic Pain
Primary: McGill Pain Questionnaire - Short Form — 10.5; 15.7; 6.0; 12.3 units on a pain scale